This section of this Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

On October 9, 2020, the existing director and officer of the Company resigned effective immediately. Accordingly, Sukhmanjit Singh, serving as a director and an officer, ceased to be the Company's Chief Executive Officer, Chief Financial Officer, President, Treasurer, Secretary and a Director. At the effective date of the resignation, Mr. Terry Wilshire consented to act as the new President and Member of the Board of Directors of the Company and Robert Dickenson consented to act as the new Vice President and Member of the Board of Directors of the Company.

On March 4, 2021, Mikrocoze, Inc. filed a Certificate of Amendment with the Secretary of State of Nevada effecting a name change on March 11, 2021 to Instadose Pharma Corp. Further on March 11, 2021, the Financial Industry Regulatory Authority approved the name change and trading symbol to "INSD".

On March 30, 2021, Instadose Pharma Corp. (the "Company") entered into an executive employment agreement (the "Agreement") with the Company's President, Terry Wilshire, effective as of April 15, 2021 (the "Executive"), pursuant to which Mr. Wilshire will continue to serve in such position. Pursuant to the terms of the Agreement, the employment of Executive terminates on December 31, 2021, but the term automatically extends year to year thereafter unless earlier terminated by either party not later than thirty (30) days prior to December 31st.

In consideration therefore, Executive will be paid a base salary of $8,000 per month. Said base salary shall not be decreased without his prior written consent. Executive will also receive a $600 car allowance (together with the monthly salary, the "Base Salary").

Upon termination by Executive of his employment for good reason or by the Company for any reason other than for "cause", the Executive shall be entitled to his Base Salary through the end of the applicable term of the Agreement. Cause is defined in the Agreement as, among others, any act or omission that constitutes a material breach which is not cured following notice by the Company and the willful and continued refusal of Executive to satisfactorily perform his duties, which failure continues after notice and the conviction of any felony or crime involving dishonesty.

The Employment Agreement contains customary confidentiality provisions during and after the term of employment of Executive. Executive also agreed that during the term of his employment with the Company and for one year thereafter he will not engage in any business which competes with the business of the Company.

Instadose Pharma Corp is focused on growth and acquisition of pharmaceutical grade agricultural products.

During the remainder of the year (If COVID-19 restrictions allow), the Company believes that is proposed acquisition of Instadose Pharma Corp. (private Corp.). will be completed by the end of July 2021. The Company intends to focus on growth and acquisition of pharmaceutical grade agriculture products continue its ongoing research. COVID-19 restrictions are beginning to lift in North America and the Company believes that there will only be minor disruption to the proposed on-going operations of the Company and will not affect it sales, operations and financings for the foreseeable future.





          4

  Table of Contents




Results of Operations

For the three-month period ended May 31, 2021 and May 31, 2020 we had no revenues, or cost of goods sold.

Expenses for the three-month period ended May 31, 2021 totaled $47,962 resulting in a net loss of $47,962. The net loss for the three-month period ended May 31, 2021 is the result of expenses of $47,962, comprised of professional fees of $38,775 which includes $17,200 in management fees; transfer agent expenses of $3,092; filing fees of $6,065; and bank service charges of $30. Expenses for the three-month period ended May 31, 2020 totaled $4,762 resulting in a net loss of $4,762. The net loss for the three-month period ended May 31, 2020 is the result of expense of $4,762, comprised of professional fees of $3,400; filing fees of $573; transfer agent expenses of $427; rent expenses of $266; telephone expense of $66; and bank service charges of $30. The increase in expenses between May 31, 2021 and May 31, 2020 is primarily due to the increase in professional fees due to the implementation of management fees during the period and the Company making application to list with OTC Markets.

For the six-month period ended May 31, 2021 and May 31, 2020 we had no revenues, or cost of goods sold.

Expenses for the six-month period ended May 31, 2021 totaled $60,131 resulting in a net loss of $60,131. The net loss for the six-month period ended May 31, 2021 is the result of expenses of $60,131, comprised of professional fees of $48,560, which includes $17,200 in management fees; transfer agent expenses of $4,663; filing fees of $6,848; and bank service charges of $60. Expenses for the six-month period ended May 31, 2020 totaled $13,606 resulting in a net loss of $13,606. The net loss for the six-month period ended May 31, 2020 is the result of expense of $13,606, comprised of professional fees of $10,900; filing fees of $573; transfer agent expenses of $1,377; rent expenses of $475; telephone expense of $128; and bank service charges of $153. The increase in expenses between May 31, 2021 and May 31, 2020 is primarily due to the increase in professional fees due to the implementation of management fees during the period and the Company making application to list with OTC Markets.

Liquidity and Capital Resources

We have generated minimal revenues to date and anticipate until we generate a more rapid growth in revenues, we will require additional financings in order to fully implement our plan of operations. With the exception of cash advances from our sole Officer and Director, and cash received in our initial offering, we have not had any additional funding. We must raise cash to implement our strategy and stay in business. Our president has verbally committed to continue to fund our operations up to $75,000. However, this is not in writing and maybe rescinded at any time.

As of May 31, 2021, we had $5 in cash and $51,130 due to a related party. As of November 30, 2020, we had 65 in cash, and $82,085 due to a related party, the former president/director of the Company . Total liabilities as of May 31, 2021, were $60,409 compared to $82,423 at November 30, 2020. The funds available to the Company will not be sufficient to fund the planned operations of the Company and maintain a reporting status. As of May 31, 2021, the Company owed $51,130, which includes $17,200 in accrued management fees. (November 30, 2020; $82,085 owed to the previous CEO of the Company) to its current Chief Executive Officer. During the six-month period ended May 31, 2021 and May 31, 2020, the CEO, paid expenses of $33,930 and $9,410, respectively, on behalf of the Company. All amounts due to the related party are unsecured, non-interest bearing and have no set terms of repayment.

On February 28, 2021, the former CEO of the Company forgave all related party loans to the Company totaling $82,085. This was reflected as an increase in Additional-Paid-In-Capital in the financial statements.

The Company is investigating the possibility of changing its business model. On December 7, 2020, Mikrocoze, Inc. (the "Company"), entered into a non-binding letter of intent (the "Letter of Intent") with Instadose Pharma Corp. ("Instadose") and holders of a majority of its outstanding shares (the "Shareholders") for a potential transaction pursuant to which the Company would acquire 100% of the outstanding common shares of Instadose (the "Acquisition") from the Shareholders in exchange for approximately 80% of the issued and outstanding shares of common stock of the Company following such exchange. As of the filing of this report a Definitive Agreement has not been completed. The anticipated consummation of the contemplated transaction is July 31, 2021.

Off-balance sheet arrangements

Other than the situation described in the section titled Capital Recourses and Liquidity, the company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company's financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.





          5

  Table of Contents

© Edgar Online, source Glimpses